ADVERTISEMENT

Clinical Summary

Type 2 diabetes: early SGLT2i initiation linked to improved CV outcomes

Miriam Tucker   |   18 November 2022

Takeaway

  • Findings support current guidelines recommending early (≤12 months) sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in patients with type 2 diabetes (T2D) with established atherosclerotic cardiovascular disease (ASCVD) or who are at high risk for it.
  • No benefit found for those without ASCVD or risk factors.

Why this matters

  • Whether...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right